Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology
JA Ajani, TA D'Amico, DJ Bentrem, D Cooke… - Journal of the National …, 2023 - jnccn.org
Cancers originating in the esophagus or esophagogastric junction constitute a major global
health problem. Esophageal cancers are histologically classified as squamous cell …
health problem. Esophageal cancers are histologically classified as squamous cell …
Preoperative chemoradiotherapy for esophageal or junctional cancer
P van Hagen, M Hulshof… - … England Journal of …, 2012 - Mass Medical Soc
Background The role of neoadjuvant chemoradiotherapy in the treatment of patients with
esophageal or esophagogastric-junction cancer is not well established. We compared …
esophageal or esophagogastric-junction cancer is not well established. We compared …
[BOOK][B] WHO classification of tumours of the digestive system.
FT Bosman, F Carneiro, RH Hruban, ND Theise - 2010 - cabidigitallibrary.org
This book is the third volume of the 4th Edition of the WHO series on histological and genetic
ty** of human tumours. It is an authoritative, concise reference book providing an …
ty** of human tumours. It is an authoritative, concise reference book providing an …
[HTML][HTML] Esophageal cancer: staging system and guidelines for staging and treatment
MF Berry - Journal of thoracic disease, 2014 - ncbi.nlm.nih.gov
Survival of esophageal cancer is improving but remains poor. Esophageal cancer stage is
based on depth of tumor invasion, involvement of regional lymph nodes, and the presence …
based on depth of tumor invasion, involvement of regional lymph nodes, and the presence …
[HTML][HTML] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell …
J Liu, Y Yang, Z Liu, X Fu, X Cai, H Li… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Camrelizumab and chemotherapy demonstrated durable antitumor activity with
a manageable safety profile as first-line treatment in patients with advanced esophageal …
a manageable safety profile as first-line treatment in patients with advanced esophageal …
Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy
R Langer, K Becker - Virchows Archiv, 2018 - Springer
Neoadjuvant therapy has been successfully introduced in the treatment of locally advanced
gastrointestinal malignancies, particularly esophageal, gastric, and rectal cancers. The …
gastrointestinal malignancies, particularly esophageal, gastric, and rectal cancers. The …
[HTML][HTML] A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal …
F Klevebro, GA von Döbeln, N Wang, G Johnsen… - Annals of …, 2016 - Elsevier
Background Neoadjuvant therapy improves long-term survival after oesophagectomy,
treating oesophageal cancer, but the evidence to date is insufficient to determine which of …
treating oesophageal cancer, but the evidence to date is insufficient to determine which of …
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study
BJ Noordman, MCW Spaander, R Valkema… - The Lancet …, 2018 - thelancet.com
Background After neoadjuvant chemoradiotherapy for oesophageal cancer, roughly half of
the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma …
the patients with squamous cell carcinoma and a quarter of those with adenocarcinoma …
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial
BJ Noordman, BPL Wijnhoven, SM Lagarde… - Bmc Cancer, 2018 - Springer
Background Neoadjuvant chemoradiotherapy (nCRT) plus surgery is a standard treatment
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …
for locally advanced oesophageal cancer. With this treatment, 29% of patients have a …
[HTML][HTML] The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma
D Shen, Q Chen, J Wu, J Li, K Tao… - Journal of …, 2021 - ncbi.nlm.nih.gov
Background Neoadjuvant therapy followed by esophagectomy has been recognized as an
effective treatment for locally advanced esophageal cancer, though still has a dismal …
effective treatment for locally advanced esophageal cancer, though still has a dismal …